By focusing on dividend income and stable businesses, investors can ensure they aren't taking on too much risk.
News & Analysis: Merck & Co.
It’s rejected a pair of drugs in the last six months.
These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.
Another quarter, another earnings beat for the big pharma company.
MRK earnings call for the period ending July 30, 2019.
Stocks dropped on Tuesday morning despite some positive earnings news from high-profile companies.
Mylan plans to merge with a spinoff from Pfizer, and Merck had more good news about its blockbuster cancer drug.
The fight against cancer is a big battle. And these 10 companies are among the biggest combatants you can invest in.
Seven steps to help you invest more effectively in the war on cancer.
Which stock wins in a head-to-head matchup between these two big drugmakers?